Omid Khalilzadeh

Omid Khalilzadeh

Auto-generated profile, based on publicly available information

Omid Khalilzadeh

Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Nutrition & Metabolism
Verified
Journal Article
Open access
PDF file
AEAlireza Esteghamati
Alireza Esteghamati
HAHaleh Ashraf
Haleh Ashraf
OKOmid Khalilzadeh
Omid Khalilzadeh
AZAli Zandieh
Ali Zandieh
MNManouchehr Nakhjavani
Manouchehr Nakhjavani
FAFereshteh Asgari
Fereshteh Asgari
We have recently determined the optimal cut-off of the homeostatic model assessment of insulin resistance for the diagnosis of insulin resistance (IR) and metabolic syndrome (MetS) in non-diabetic residents of Tehran, the capital of Iran. The aim of the present study is to establish the optimal cut-off at the national level in the Iranian population with and without diabetes. Data of the third National Surveillance of Risk Factors of Non-Communicable Diseases, available for 3,071 adult Iranian individuals aging 25-64 years were analyzed. MetS was defined according to the Adult Treatment Panel III (ATPIII) and International Diabetes Federation (IDF) criteria. HOMA-IR cut-offs from the 50th to the 95th percentile were calculated and sensitivity, specificity, and positive likelihood ratio for MetS diagnosis were determined. The receiver operating characteristic (ROC) curves of HOMA-IR for MetS diagnosis were depicted, and the optimal cut-offs were determined by two different methods: Youden index, and the shortest distance from the top left corner of the curve. The area under the curve (AUC) (95%CI) was 0.650 (0.631-0.670) for IDF-defined MetS and 0.683 (0.664-0.703) with the ATPIII definition. The optimal HOMA-IR cut-off for the diagnosis of IDF- and ATPIII-defined MetS in non-diabetic individuals was 1.775 (sensitivity: 57.3%, specificity: 65.3%, with ATPIII; sensitivity: 55.9%, specificity: 64.7%, with IDF). The optimal cut-offs in diabetic individuals were 3.875 (sensitivity: 49.7%, specificity: 69.6%) and 4.325 (sensitivity: 45.4%, specificity: 69.0%) for ATPIII- and IDF-defined MetS, respectively. We determined the optimal HOMA-IR cut-off points for the diagnosis of MetS in the Iranian population with and without diabetes.

29 December 2013 in Vision Research
Verified
Journal Article
Closed access
PDF file
JBJi Won Bang
Ji Won Bang
OKOmid Khalilzadeh
Omid Khalilzadeh
MHMatti Hamalainen
Matti Hamalainen
TWTakeo Watanabe
Takeo Watanabe
YSYuka Sasaki
Yuka Sasaki

1 December 2011 in Current Genomics
Verified
Journal Article
Open access
PDF file
OKOmid Khalilzadeh
Omid Khalilzadeh
SNSina Noshad
Sina Noshad
ARArmin Rashidi
Armin Rashidi
AAAliakbar Amirzargar
Aliakbar Amirzargar
Graves disease (GD) is the most common cause of thyrotoxicosis and often involves the orbits. Graves ophthalmopathy (GO), also known as Thyroid Eye Disease (TED), can be clinically significant and advance to sightthreatening stages. Our knowledge of the immunogenetic pathophysiology of GO is rapidly expanding. The present review is an attempt to summarize the current state of knowledge on the immunogenetics of GO. First we briefly review the epidemiology and clinical importance of GO, and then we describe in detail the macromolecular pathogenesis and finally immunogenetics of GO. Discrepancies between the results from various reports and the limitations of the available data are discussed. In particular, there is a scarcity of data from non-Asian populations. While several studies have demonstrated significant associations between polymorphisms in certain genes (especially CTLA-4, HLA-DRB-1, and TNF-α), there is a need for studies that investigate the relationship between polymorphisms and both serum and local concentrations of the resulting proteins. A complete understanding of GO susceptibility and pathogenesis has not been yet possible due to a number of important knowledge gaps that need to be filled by future research.

8 June 2010 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
AEAlireza Esteghamati
Alireza Esteghamati
AZAli Zandieh
Ali Zandieh
OKOmid Khalilzadeh
Omid Khalilzadeh
AMAlipasha Meysamie
Alipasha Meysamie
HAHaleh Ashraf
Haleh Ashraf
Metabolic syndrome (MetS) encompasses a cluster of coronary heart disease and diabetes mellitus risk factors. In this study, we aimed to elucidate the factors underlying the clustering of MetS components in diabetic and non-diabetic individuals.

13 December 2011 in Clinical Neuroradiology
Verified
Journal Article
Closed access
PDF file
SAShahram Akhlaghpour
Shahram Akhlaghpour
AGA. Ghahari
A. Ghahari
AMA. Morteza
A. Morteza
OKO. Khalilzadeh
O. Khalilzadeh
ASA. Shakourirad
A. Shakourirad
MAM. R. Alinaghizadeh
M. R. Alinaghizadeh

13 February 2012 in Gene
Verified
Journal Article
Closed access
MNManouchehr Nakhjavani
Manouchehr Nakhjavani
AMAfsaneh Morteza
Afsaneh Morteza
FAFiruzeh Asgarani
Firuzeh Asgarani
OKOmid Khalilzadeh
Omid Khalilzadeh
ZGZaniar Ghazizadeh
Zaniar Ghazizadeh
AEAlireza Esteghamati
Alireza Esteghamati